07/03/2022Published by Fondazione Gianni Bonadonna at 07/03/2022Categories Events UncategorizedTargeted protein degradation to tackle ‘undruggable targets’
28/02/2022Published by Fondazione Gianni Bonadonna at 28/02/2022Categories Events UncategorizedTriple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial
21/02/2022Published by Fondazione Gianni Bonadonna at 21/02/2022Categories Events UncategorizedHER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab and palbociclib
14/02/2022Published by Fondazione Gianni Bonadonna at 14/02/2022Categories Events UncategorizedDabrafenib and trametinib in anaplastic thyroid cancer
07/02/2022Published by Fondazione Gianni Bonadonna at 07/02/2022Categories Events UncategorizedTwo female researchers win the first edition of the Fellowship named after Gianni Bonadonna
31/01/2022Published by Fondazione Gianni Bonadonna at 31/01/2022Categories Events UncategorizedEncouraging results with polatuzumab vedotin in lymphoma patients
24/01/2022Published by Fondazione Gianni Bonadonna at 24/01/2022Categories Events UncategorizedAdvanced melanoma, encouraging results with relatlimab e nivolumab
17/01/2022Published by Fondazione Gianni Bonadonna at 17/01/2022Categories Events UncategorizedLung cancer benefits from the combination of EGFR-TK inhibitors and patritumab deruxtecan
10/01/2022Published by Fondazione Gianni Bonadonna at 10/01/2022Categories Events UncategorizedHow to predict breast cancer therapy response
